8-K: Arcellx Announces Promising Clinical Data for Anito-cel in Multiple Myeloma and Progress in iMMagine-3 Study

Arcellx reported highly encouraging clinical data for its anito-cel therapy in relapsed or refractory multiple myeloma, including a 95% overall response rate in a Phase 2 study, and announced the first patient dosed in the iMMagine-3 study.

Summary

• Arcellx has released updated clinical data for its anito-cel therapy in patients with relapsed or refractory multiple myeloma (RRMM).
• The Phase 1 study showed a 30.2-month median progression-free survival with a median follow-up of 38.1 months, and the median overall survival was not reached.
• Preliminary results from the Phase 2 iMMagine-1 study, involving 58 patients, demonstrated a 95% overall response rate (ORR) and a 62% complete response/stringent complete response (CR/sCR) rate at a median follow-up of 10.3 months.
• 92% of patients evaluable for minimal residual disease (MRD) testing in the iMMagine-1 study achieved MRD negativity.
• The 6-month progression-free survival (PFS) and overall survival (OS) rates were estimated at 90% and 95%, respectively, in the iMMagine-1 study.
• No delayed neurotoxicities were observed in either the Phase 1 or iMMagine-1 studies across more than 140 patients dosed.
• The first patient has been dosed in the iMMagine-3 study, which is a global Phase 3 randomized controlled study.
• Arcellx will present these results at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024.
• A webcast event with an expert panel of clinicians will be held on December 9, 2024, to discuss the clinical results.

Sentiment

Score: 9

Explanation: The document presents very positive clinical data for anito-cel, with high response rates and manageable safety, suggesting a strong potential for the therapy. The initiation of the Phase 3 study further reinforces the positive outlook.

Positives

• Anito-cel shows a high overall response rate of 95% in the iMMagine-1 study.
• The complete response/stringent complete response rate is 62% in the iMMagine-1 study.
• A high percentage of patients, 92%, achieved MRD negativity in the iMMagine-1 study.
• The median progression-free survival of 30.2 months in the Phase 1 study is very promising.
• The safety profile of anito-cel appears manageable with no delayed neurotoxicities observed.
• The iMMagine-3 study has commenced with the first patient dosed.
• The 6-month progression-free survival (PFS) and overall survival (OS) rates were estimated at 90% and 95%, respectively, in the iMMagine-1 study.

Negatives

• Three deaths occurred due to adverse events in the iMMagine-1 study, though these were both related and unrelated to the treatment.
• Cytopenias, such as neutropenia, thrombocytopenia, and anemia, were common Grade 3 treatment-emergent adverse events.

Risks

• The study reported three deaths due to adverse events, highlighting potential risks associated with the treatment.
• Cytopenias were common Grade 3 treatment-emergent adverse events, indicating potential hematological risks.
• The long-term efficacy and safety of anito-cel are still being evaluated in ongoing studies.
• The iMMagine-3 study is still in its early stages, and its results are not yet available.

Future Outlook

Arcellx plans to continue the clinical development of anito-cel, including the ongoing iMMagine-3 study, and anticipates further data announcements. The company also expects a potential commercial launch of anito-cel, subject to FDA approval.

Management Comments

• Arcellx is reimagining cell therapy through the development of innovative immunotherapies.
• Arcellx believes that cell therapies are one of the forward pillars of medicine.
• Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible.

Industry Context

This announcement is significant in the context of the evolving landscape of multiple myeloma treatment, where there is a need for more effective and durable therapies, particularly for patients with relapsed or refractory disease. The results of the anito-cel studies are promising compared to existing treatments, and the collaboration with Kite positions Arcellx well for commercialization.

Comparison to Industry Standards

• The 95% ORR and 62% CR/sCR in the iMMagine-1 study are very competitive compared to other CAR T-cell therapies for multiple myeloma, such as Abecma and Carvykti, which have shown ORRs in the 70-80% range and CR/sCR rates in the 30-40% range in similar patient populations.
• The 30.2-month median PFS in the Phase 1 study is also notable, as many existing therapies have shorter PFS durations.
• The absence of delayed neurotoxicities is a significant advantage compared to some other CAR T-cell therapies, which have been associated with such side effects.
• The iMMagine-3 study, comparing anito-cel to standard of care, will provide further insight into its efficacy and safety compared to established treatments like pomalidomide, bortezomib, and daratumumab combinations.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical data and progress in the iMMagine-3 study.
• Patients with relapsed or refractory multiple myeloma may benefit from the promising results of anito-cel.
• Employees of Arcellx will be motivated by the positive clinical outcomes and the potential for commercial success.
• The collaboration with Kite will provide a strong commercialization pathway for anito-cel.

Next Steps

• Arcellx will present updated clinical data at the 66th ASH Annual Meeting and Exposition in December 2024.
• The company will host a webcast event on December 9, 2024, to discuss the clinical results.
• The iMMagine-3 study will continue to enroll patients and evaluate the efficacy and safety of anito-cel.
• Arcellx will continue to monitor patients in the Phase 1 and iMMagine-1 studies for long-term outcomes.

Key Dates

Keywords

anito-cel, multiple myeloma, cell therapy, immunotherapy, CAR T-cell therapy, iMMagine-1, iMMagine-3, ASH, progression-free survival, overall response rate, minimal residual disease, neurotoxicity